Kiniksa Pharmaceuticals International PLC
KNSA32.125USD
+0.145+0.45%
Market hours （ET）Quotes delayed by 15 min
2.38BMarket Cap
LossP/E TTM
More Details of Kiniksa Pharmaceuticals International PLC Company
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or validated mechanisms, targets a spectrum of underserved cardiovascular and autoimmune conditions and offers the potential for differentiation. ARCALYST is an interleukin-1α and interleukin-1β cytokine trap. ARCALYST is used for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist.
Company Info
Ticker SymbolKNSA
Company nameKiniksa Pharmaceuticals International PLC
IPO dateMay 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
Number of employees315
Security typeOrdinary Share
Fiscal year-endMay 24
Address23 Old Bond Street, Floor 3
CityLONDON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeWIS 4PZ
Phone
Websitehttps://www.kiniksa.com/
Ticker SymbolKNSA
IPO dateMay 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 22
Updated: Thu, May 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Shareholders
Shareholders
Proportion
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
Shareholder Types
Shareholders
Proportion
Hedge Fund
41.14%
Investment Advisor
27.15%
Investment Advisor/Hedge Fund
25.63%
Individual Investor
3.86%
Research Firm
2.27%
Pension Fund
0.59%
Bank and Trust
0.30%
Insurance Company
0.11%
Family Office
0.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
393
42.78M
98.41%
-554.60K
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
2023Q1
303
35.17M
100.37%
-5.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rubric Capital Management LP
3.38M
7.99%
+764.14K
+29.18%
Mar 31, 2025
The Vanguard Group, Inc.
3.35M
7.91%
+151.60K
+4.74%
Mar 31, 2025
Baker Bros. Advisors LP
2.82M
6.66%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
5.94%
-39.60K
-1.55%
Mar 31, 2025
Tang Capital Management, LLC
2.12M
5%
+1.49M
+237.03%
Mar 31, 2025
Braidwell LP
1.96M
4.64%
-1.49M
-43.14%
Mar 31, 2025
Point72 Asset Management, L.P.
1.15M
2.71%
+1.15M
--
Mar 31, 2025
Pictet Asset Management Ltd.
1.13M
2.68%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
1.10M
2.6%
+1.10M
--
Mar 31, 2025
Desnick (Robert)
1.05M
2.48%
--
--
Apr 08, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.92%
First Trust Active Factor Small Cap ETF
0.54%
VictoryShares Small Cap Free Cash Flow ETF
0.53%
iShares Health Innovation Active ETF
0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.15%
WisdomTree US SmallCap Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
Fidelity Enhanced Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.04%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.92%
First Trust Active Factor Small Cap ETF
Proportion0.54%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.53%
iShares Health Innovation Active ETF
Proportion0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proportion0.15%
WisdomTree US SmallCap Fund
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
Fidelity Enhanced Small Cap ETF
Proportion0.11%
iShares Micro-Cap ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
